文献速递慢阻肺

美国支气管镜肺减容术住院并发症发生率

Inpatient Complication Rates of Bronchoscopic Lung Volume Reduction in the United States.
PubMed 文献 · Chest · 2024-08-23

基于美国全国住院患者样本数据库2018至2020年数据,识别467例支气管镜肺减容术住院病例,发现真实世界并发症发生率与早期随机对照试验相似,气胸发生率为26.3%,住院死亡率低(少于11例,<2.3%),提示该疗法对重度肺气肿安全。

要点

  • BLVR术后气胸发生率26.3%,其中68.3%需置入胸腔引流管。
  • 急性呼吸衰竭发生率19.5%,COPD急性加重8.8%,肺炎7.3%,咯血5.3%。
  • 住院死亡率低于2.3%,真实世界并发症谱与早期RCT相似。

核心结论

  • 真实世界BLVR术后并发症发生率与早期随机对照试验报道相似,住院死亡率低,除常见预期并发症外,BLVR是重度肺气肿的安全治疗选择。

研究设计与样本

  • 使用美国全国住院患者样本数据库,识别2018年至2020年BLVR相关住院并发症,共纳入467例住院病例。

主要发现

  • 2019年至2020年手术量翻倍(从153例增至295例)。
  • 中位年龄67.9岁(四分位距61.1-72.8岁),女性210例(45.0%),白人401例(85.8%),Medicare为主要支付方占72.8%。
  • 气胸发生率26.3%,急性呼吸衰竭19.5%,COPD急性加重8.8%,肺炎7.3%,咯血5.3%。
  • 123例气胸患者中84例(68.3%)需置入胸腔引流管,69例(14.8%)需移除支气管内活瓣。
  • 中位住院时间2.8天(四分位距2.3-4.5天),住院死亡少于11例(<2.3%)。

关键数值与推荐

  • 并发症定义包括气胸、COPD急性加重、肺炎、咯血、急性呼吸衰竭和活瓣移除。
  • 发生住院并发症的亚组在合并症、人口学特征和医院特征方面与其余患者无显著差异。

临床怎么用

  • 临床应预期BLVR术后气胸和急性呼吸衰竭风险较高,需做好胸腔引流准备。
  • 真实世界住院死亡率低,支持在重度肺气肿患者中开展BLVR。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Early randomized controlled trials (RCTs) of bronchoscopic lung volume reduction (BLVR) have shown clinically meaningful benefits in lung function, dyspnea, and quality of life in patients with severe emphysema. Safety outcome data obtained after BLVR in the United States are scarce outside the RCTs. RESEARCH QUESTION: What is the rate of inpatient complications after BLVR in the real world in the United States? STUDY DESIGN AND METHODS: We used the National Inpatient Sample database to identify in-hospital complications after BLVR from 2018 through 2020. Complications were defined as pneumothorax, COPD exacerbation, pneumonia, hemoptysis, acute respiratory failure, and valve removal. We also analyzed all-cause in-hospital mortality and length of stay (LOS). RESULTS: We identified 467 admissions related to BLVR procedures. The number of procedures doubled between 2019 and 2020 (from 153 to 295 procedures). The median age was 67.9 years (interquartile range, 61.1-72.8 years), 210 patients (45.0%) were female, 401 patients (85.8%) were White, and Medicare was the primary expected payer for 72.8% of patients. Most procedures were performed in urban teaching hospitals (56.9%). The rate of pneumothorax was 26.3%, that of acute respiratory failure was 19.5%, that of COPD exacerbation was 8.8%, that of pneumonia was 7.3%, and that of hemoptysis was 5.3%. Chest tube placement was required in 84 of 123 patients (68.3%) with pneumothorax. The endobronchial valve had to be removed in 69 patients (14.8%). The median LOS was 2.8 days (interquartile range, 2.3-4.5 days). The number of in-hospital deaths was fewer than 11 (< 2.3%). Overall, the subgroup who experienced in-hospital complications did not differ significantly from the others in terms of comorbidities, demographics, and hospital characteristics. INTERPRETATION: We found that the real-world complication rate after BLVR was similar to the published complication rates from early randomized clinical trials. In-hospital mortality was low, suggesting that aside from the commonly anticipated complications, BLVR is a safe treatment option for severe emphysema.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Costa Filho, Buckley, Furlan, et al. Inpatient Complication Rates of Bronchoscopic Lung Volume Reduction in the United States. Chest. 2024. PMID: 39181376. doi:10.1016/j.chest.2024.08.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。